Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00655655 · ClinicalTrials.gov registry record · Phase 1

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

A Phase 1 study of Recurrent Melanoma and Insulinoma, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
96
Enrollment target
1
Study location

NCT00655655 is a Phase 1 study of Recurrent Melanoma and Insulinoma that has completed, run by Mayo Clinic. The registered enrollment target is 96 participants, below the 169-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00655655, a Phase 1 study of Recurrent Melanoma and Insulinoma, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

Conditions Studied

Recurrent Melanoma Insulinoma Metastatic Gastrointestinal Carcinoid Tumor Gastrinoma Glucagonoma Pancreatic Polypeptide Tumor Recurrent Islet Cell Carcinoma Recurrent Gastrointestinal Carcinoid Tumor Metastatic Pheochromocytoma Recurrent Neuroendocrine Carcinoma of the Skin

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER pharmacological study
  • DRUG everolimus
  • PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
  • DRUG vatalanib

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2004-12
Est. Completion 2018-01-11
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00655655

The ClinicalTrials.gov registry entry for NCT00655655 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (43% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT00655655 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00655655 about?

NCT00655655 is a clinical study titled "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors". RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and be...

What is the current status of trial NCT00655655?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2004-12. Estimated completion is 2018-01-11.

What conditions does trial NCT00655655 study?

This clinical trial studies the following conditions: Recurrent Melanoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Gastrinoma, Glucagonoma.

What interventions are being tested in trial NCT00655655?

The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), everolimus (DRUG), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), vatalanib (DRUG).

Who is sponsoring clinical trial NCT00655655?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00655655 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Melanoma

All registered trials for this condition

Insulinoma

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.